Lorenz C Hofbauer
Hofbauer, Lorenz 1968-
Hofbauer, Lorenz Christian, 1968-
VIAF ID: 85739015 (Personal)
Permalink: http://viaf.org/viaf/85739015
Preferred Forms
-
- 100 1 _ ‡a Hofbauer, Lorenz ‡d 1968-
- 100 0 _ ‡a Lorenz C Hofbauer
4xx's: Alternate Name Forms (4)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
Immunprofil von Patienten mit fortgeschrittenen Myelodysplastischen Syndromen oder Akuten Myeloischen Leukämien unter der gegen CD123 gerichteten Therapie mit Talacotuzumab | |
Minireview: live and let die: molecular effects of glucocorticoids on bone cells. | |
miR-125b regulates calcification of vascular smooth muscle cells | |
[The molecular pathogenesis of obesity. The physiological and pathophysiological role of leptin] | |
Monitoring of the first stages of bone healing with microdialysis. | |
More DATA to guide sequential osteoporosis therapy. | |
Multimodal therapy for vertebral involvement of systemic mastocytosis. | |
Myelodysplasia is in the niche: novel concepts and emerging therapies | |
Myelodysplastic syndromes and bone loss in mice and men. | |
NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis | |
The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. | |
Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease | |
Novel therapies in benign and malignant bone diseases. | |
Oncologic resection achieving r0 margins improves disease-free survival in parathyroid cancer | |
Optimizing management of myelodysplastic syndromes post-allogeneic transplantation | |
Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats | |
Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking the transcription factor NFATc2. | |
Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy | |
Osteopetrosis in cathepsin K-deficient mice | |
Osteoporosis: now and the future | |
Osteoporosis treatment: recent developments and ongoing challenges | |
Osteoprotegerin: a link between osteoporosis and arterial calcification? | |
Osteoprotegerin: a new biomarker for impaired bone metabolism in complex regional pain syndrome? | |
Osteoprotegerin expression in dendritic cells increases with maturation and is NF-kappaB-dependent | |
Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease | |
[Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases] | |
Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis | |
Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs. | |
p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells | |
Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. | |
[The pathogenesis, diagnosis and therapy of posttransplantation osteoporosis] | |
Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I. | |
Pheochromocytoma - update on disease management | |
Prediction of Fractures and Major Cardiovascular Events in Men Using Serum Osteoprotegerin Levels: The Prospective STRAMBO Study | |
The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience | |
The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice | |
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells | |
[Problems and controversies in the treatment of ankle fractures] | |
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis | |
The promotion of osteoclastogenesis by sulfated hyaluronan through interference with osteoprotegerin and receptor activator of NF-κB ligand/osteoprotegerin complex formation | |
Prospects of adjuvant RANKL inhibition in breast cancer? | |
Pulmonary metastases due to a giant-cell tumor of bone | |
Regenerative potential of glycosaminoglycans for skin and bone. | |
Regulation of bone mass and osteoclast function depend on the F-actin modulator SWAP-70. | |
Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. | |
Regulation of VEGF by mevalonate pathway inhibition in breast cancer | |
Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. | |
Rheumatoid arthritis, neutropenia and splenomegaly: the Felty syndrome | |
Role of milk fat globule-epidermal growth factor 8 in osteoimmunology | |
The role of osteoclast-associated receptor in osteoimmunology. | |
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | |
Romosozumab Treatment in Postmenopausal Women with Osteoporosis | |
Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. | |
Seizures associated with zoledronic acid for osteoporosis | |
Selective glucocorticoid receptor modulation maintains bone mineral density in mice | |
Serum measurement of osteoprotegerin--clinical relevance and potential applications | |
Severe abdominal aortic calcification in older men is negatively associated with DKK1 serum levels: the STRAMBO study. | |
Site-Specific Variations in Bone Mineral Density under Systemic Conditions Inducing Osteoporosis in Minipigs | |
Skeletal and extraskeletal actions of denosumab. | |
Skeletal and soft tissue involvement in Mazabraud syndrome | |
Skeletal effects of cyclosporin A are gender related in rats. | |
Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes. | |
Structural and functional insights into sclerostin-glycosaminoglycan interactions in bone | |
Sulfated glycosaminoglycans support osteoblast functions and concurrently suppress osteoclasts. | |
Sulfated hyaluronan improves bone regeneration of diabetic rats by binding sclerostin and enhancing osteoblast function | |
Sweet and brittle — Diabetes mellitus and the skeleton | |
Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. | |
Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin. | |
Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. | |
Thyrotropin serum levels are differentially associated with biochemical markers of bone turnover and stiffness in women and men: results from the SHIP cohorts | |
[Transforming growth factor beta as a protective factor in autoimmune pancreatitis] | |
Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis | |
VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors | |
Vitamin D receptor knock-out mice: the expectational and the exceptional. | |
WNT5A and Its Receptors in the Bone-Cancer Dialogue. | |
WNT5A has anti-prostate cancer effects in vitro and reduces tumor growth in the skeleton in vivo | |
Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors | |
WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production | |
Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells | |
Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. |